Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Sci Adv ; 6(50)2020 12.
Article in English | MEDLINE | ID: mdl-33310846

ABSTRACT

A functional lymphatic vasculature is essential for tissue fluid homeostasis, immunity, and lipid clearance. Although atherosclerosis has been linked to adventitial lymphangiogenesis, the functionality of aortic lymphatic vessels draining the diseased aorta has never been assessed and the role of lymphatic drainage in atherogenesis is not well understood. We develop a method to measure aortic lymphatic transport of macromolecules and show that it is impaired during atherosclerosis progression, whereas it is ameliorated during lesion regression induced by ezetimibe. Disruption of aortic lymph flow by lymphatic ligation promotes adventitial inflammation and development of atherosclerotic plaque in hypercholesterolemic mice and inhibits ezetimibe-induced atherosclerosis regression. Thus, progression of atherosclerotic plaques may result not only from increased entry of atherogenic factors into the arterial wall but also from reduced lymphatic clearance of these factors as a result of aortic lymph stasis. Our findings suggest that promoting lymphatic drainage might be effective for treating atherosclerosis.


Subject(s)
Atherosclerosis , Plaque, Atherosclerotic , Animals , Aorta/pathology , Atherosclerosis/drug therapy , Atherosclerosis/pathology , Ezetimibe/pharmacology , Ezetimibe/therapeutic use , Lymphangiogenesis , Mice , Plaque, Atherosclerotic/drug therapy , Plaque, Atherosclerotic/pathology
2.
Oncotarget ; 6(42): 44806-18, 2015 Dec 29.
Article in English | MEDLINE | ID: mdl-26575174

ABSTRACT

Resection of infiltrated tumor-draining lymph nodes (TDLNs) is a standard practice for the treatment of several cancers including breast cancer and melanoma. However, many randomized prospective trials have failed to show convincing clinical benefits associated with LN removal and the role of TDLNs in cancer dissemination is poorly understood. Here, we found in a well-characterized spontaneous mouse model of uveal melanoma that the growth of the primary tumor was accompanied by increased lymphangiogenesis and cancer cell colonization in the LNs draining the eyes. But, unexpectedly, early resection of the TDLNs increased the growth of the primary tumor and associated blood vessels as well as promoted cancer cell survival and dissemination. These effects were accompanied by increased tumor cell proliferation and expression of phosphorylated AKT. Topical application of a broad anti-inflammatory agent, Tobradex, or an oral treatment with cyclooxygenase-2 specific inhibitor, Celecoxib, reversed tumor progression observed after complete lymphadenectomy. Our study confirms the importance of tumor homeostasis in cancer progression by showing the enhancing effects of TDLN removal on tumor growth and cancer cell dissemination, and suggests that TDLN resection may only be beneficial if used in combination with anti-inflammatory drugs such as Tobradex and Celecoxib.


Subject(s)
Cell Movement , Cell Proliferation , Lymph Node Excision/adverse effects , Melanoma/surgery , Neoplasms, Experimental/surgery , Uveal Neoplasms/surgery , Animals , Cell Movement/drug effects , Cell Proliferation/drug effects , Cyclooxygenase 2 Inhibitors/pharmacology , Disease Progression , Female , Genetic Predisposition to Disease , Humans , Male , Melanoma/genetics , Melanoma/metabolism , Melanoma/secondary , Mice , Mice, Transgenic , Neoplasms, Experimental/genetics , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/pathology , Neovascularization, Pathologic , Phenotype , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-ret/genetics , Time Factors , Tumor Burden , Uveal Neoplasms/genetics , Uveal Neoplasms/metabolism , Uveal Neoplasms/pathology , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-1/metabolism
3.
Cell Transplant ; 20(11-12): 1827-41, 2011.
Article in English | MEDLINE | ID: mdl-21439131

ABSTRACT

In this study we describe the derivation and immunological characterization of a primary epithelial cell type from the human umbilical cord membrane. These cord lining epithelial cells (CLECs) expressed and/or secreted isoforms of the nonclassical human leukocyte antigen class I (HLA-1b) glycoproteins, HLA-G and E. Conditioned media from CLECs inhibited mitogen-stimulated T-lymphocyte responses, and in a mixed leukocyte reaction (MLR) assay, cocultured CLECs inhibited allogeneic responses with a concomitant reduction in proinflammatory cytokines. Using a transwell coculture system, it was demonstrated that these immunoregulatory effects were mediated by soluble factors secreted by CLECs, in a dose-dependent manner. Functional studies using HLA-G blocking antibody showed that the effects of CLEC-secreted products could be inhibited, thus demonstrating a significant and important role for soluble HLA-G. In vivo, we show that transplanted CLECs could be maintained for extended periods in immunocompetent mice where xenorejection rapidly destroyed primary keratinocytes, a control human epithelial cell type. Additionally, CLECs delayed the rejection of keratinocytes and extended their survival when cotransplanted, indicating an ability to protect adjacent human cell types that would otherwise be rejected if transplanted alone. We also show that CLECs transduced with a modified human proinsulin gene were transplanted intraperitoneally into streptozotocin (STZ)-induced diabetic mice, resulting in significantly lower levels of serum glucose compared to control mice. This study has characterized the immunological properties of CLECs and tested a potential therapeutic application in the treatment of a type 1 diabetes mouse model.


Subject(s)
Epithelial Cells/metabolism , Fetal Blood/cytology , Animals , Blood Glucose/analysis , Cells, Cultured , Diabetes Mellitus, Experimental/therapy , Epithelial Cells/cytology , Epithelial Cells/transplantation , Graft Rejection/immunology , Graft Rejection/pathology , Graft Survival/immunology , HLA-G Antigens/immunology , HLA-G Antigens/metabolism , Histocompatibility Antigens Class I/immunology , Histocompatibility Antigens Class I/metabolism , Humans , Keratinocytes/cytology , Keratinocytes/transplantation , Leukocytes, Mononuclear/cytology , Mice , Mice, SCID , Proinsulin/genetics , Proinsulin/metabolism , Transplantation, Heterologous , HLA-E Antigens
SELECTION OF CITATIONS
SEARCH DETAIL